Casi to create ‘key asset’ manufacturing facility in China

By Ben Hargreaves

- Last updated on GMT

(Image: Getty/Rawpixel)
(Image: Getty/Rawpixel)

Related tags Casi Pharmaceuticals China Sandoz Fda

The US company will complete a ‘large-scale’ manufacturing facility to support production in the next three to five years.

Casi Pharmaceuticals continues its push into the Chinese market with plans to develop a manufacturing facility in Jiangsu Province, China.

The firm has already in-licensed three US Food and Drug Administration (FDA) approved products from Spectrum Pharmaceuticals specifically for China. It also holds a Beijing-based subsidiary and R&D operations in the country.

A spokesperson for Casi told us the facility will take three to five years to complete construction work, receive FDA approval and then scale up production.

“The project will be completed in phases. For the first phase, we expect to file with the FDA for changing manufacturing site approvals of our first key ANDA (abbreviated new drug application) product in two years,”​ the spokesperson continued.

Construction of the facility will begin in mid-2019 and the firm said in a statement that it will be “a key asset supporting Casi’s growth and commercialisation plans with further agreements to be finalised”.

In terms of the cost of the facility, the company will invest $21m (€18.4m) and will receive $20m from an undisclosed “joint venture partner”, ​the spokesperson said.

It will also invest several ANDA products into the joint venture, which the company values at, or above, $30m.

The spokesperson was unable to confirm which products will be produced at the site but said that the company is “evaluating the market potential” ​of 30 ANDA products to be produced at the site – with China and the US the intended markets.

At the beginning of the year​, Casi acquired a portfolio of 25 ANDA products from Sandoz, a subsidiary of Novartis, with the intention of producing these assets for the Chinese market.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more